MoonLake: Sonelokimab Phase 3 Week 40 Shows 62% Response: MoonLake reports 62% Week 40 clinical response for sonelokimab in Phase 3 VELA trials (Mar 28, 2026); full safety and endpoint details pending. 👈 Read full analysis #MoonLake #Sonelokimab #ClinicalTrials #Phase3 #AADMeeting
0
0
0
0